NCT05972655View on ClinicalTrials.gov

Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 2, 2023

Primary Completion Date

August 20, 2024

Study Completion Date

May 1, 2026

Conditions
Low Rectal Cancer
Interventions
RADIATION

Modified short-course radiotherapy

radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx

DRUG

PD-1 antibody

PD-1 antibody (Tislelizumab): 200mg d1 q3w

DRUG

Capecitabine

Capecitabine: 1000mg/m2 d1-14 q3w

DRUG

Oxaliplatin

Oxaliplatin: 130mg/m2 d1 q3w

Trial Locations (1)

310012

RECRUITING

Sir Run Run Shao hospital, Hanzhou

All Listed Sponsors
lead

Sir Run Run Shaw Hospital

OTHER